CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Subcutaneous Fat
Conditions
Subcutaneous Fat
Trial Timeline
Nov 10, 2023 → Oct 18, 2024
NCT ID
NCT06005441About CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride
CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT06005441. Target conditions include Subcutaneous Fat.
What happened to similar drugs?
0 of 3 similar drugs in Subcutaneous Fat were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06005441 | Phase 2 | Completed |
Competing Products
9 competing products in Subcutaneous Fat
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TR-701 FA + Linezolid | Merck | Phase 3 | 40 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 40 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514, placebo + CBL-514, placebo + CBL-514 | Caliway Biopharmaceuticals | Phase 1 | 29 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 3 | 47 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 35 |